IAB exhibits superior ADCC activity in vitro and minimal blood toxicity in vivo. (A) Relative ADCC activity of IAB, CV1 Fc and atezolizumab in ADCC reporter assay. (n = 3); Analysis of red blood cell (B), hematocrit (C) and hemoglobin (D) in mice intraperitoneal injected with 100 mg/Kg of IAB or parental proteins (n = 5). Data are reported as the means ± SD, *: p<0.05, **: p <0.01, ***: p <0.001; NS: non-significant (unpaired Student's t test).